Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECT-FD bezafibrate crossover trial in familial dysbetalipoproteinemia
NL-OMON29530Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bezafibrate in dysbetalipoproteinemia (DBL) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Post fatload non-HDL cholesterol. Planned start Jul 2015; status: not yet recruiting.
02
Drugs
bezafibrate
03
Conditions
dysbetalipoproteinemia (DBL)
Beyond the preview
Go deeper on NL-OMON29530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29530.